eFFECTOR Therapeutics, Inc. (EFTR)
OTCMKTS
· Delayed Price · Currency is USD
0.0003
0.00 (0.00%)
Jun 12, 2025, 8:00 PM EDT
eFFECTOR Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
1.41K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.55M | 2.12M | 148.46% |
| Dec 31, 2021 | 1.43M | -40.57M | -96.60% |
| Dec 31, 2020 | 42.00M | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Elite Pharmaceuticals | 70.00M |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Northwest Biotherapeutics | 1.47M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
eFFECTOR Therapeutics News
- 7 months ago - BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board - Newsfile Corp
- 1 year ago - eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq - GlobeNewsWire
- 1 year ago - eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewsWire
- 1 year ago - eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - eFFECTOR Therapeutics to Participate in Upcoming Investor Conference - GlobeNewsWire
- 1 year ago - eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer - GlobeNewsWire
- 1 year ago - eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire